Investing.com - Avalo Therapeutics reported on Monday third quarter earnings that beat analysts' forecasts and revenue that topped expectations.
Avalo Therapeutics announced earnings per share of $0.340 on revenue of $14.95M. Analysts polled by Investing.com anticipated EPS of $-0.878 on revenue of $1.26M.
Avalo Therapeutics shares are down 11% from the beginning of the year and are trading at $6.759 , down-from-52-week-high.
Avalo Therapeutics shares gained 0.28% in intra-day trade following the report.
Avalo Therapeutics follows other major Healthcare sector earnings this month
Avalo Therapeutics's report follows an earnings beat by UnitedHealth on Friday, October 14, 2022, who reported EPS of $5.79 on revenue of $80.89B, compared to forecasts EPS of $5.43 on revenue of $80.52B.
J&J had beat expectations on Tuesday, October 18, 2022 with third quarter EPS of $2.55 on revenue of $23.79B, compared to forecast for EPS of $2.52 on revenue of $23.46B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar